Otamixaban

DB06635InvestigationalSmall molecule

Otamixaban is a novel direct Factor Xa (FXa) inhibitor. It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.

Mechanism: Pharmacologically active on Coagulation factor X
Curator reviewed
Primary indication: Investigated for use/treatment in thrombosis.Curator reviewed
Formula / weight: C₂₅H₂₆N₄O₄ · 446.4983 g/mol (avg)
Code names: FXV-673 · RPR-130673 · XRP-0673

Resolves to

Compound

UNIIS173RED00LCAS193153-04-7ChEMBLCHEMBL46618PubChem5496659

Structure

InChIKeyPFGVNLZDWRZPJW-OPAMFIHVSA-NSMILESCOC(=O)[C@H](CC1=CC(=CC=C1)C(N)=N)[C@@H](C)NC(=O)C1=CC=C(C=C1)C1=CC=[N+]([O-])C=C1

Targets

P00742F10

What you can answer from here — as of August 29, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

642Drug interactionsStructured to mechanism, not free text

4Clinical trialsPhase, status and sponsor resolved per trial

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Otamixaban, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account